Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | MAOB | P27338 | 3/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.61 |
| ▸ | MITF | O75030 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hiazolidinedione1 SCHEMBL12652927 | 1.00 | MAPK1 (1.00) | MAPK1MAOAMAOBCISD1MITF | |
| Hiazolidinedione1 SCHEMBL569132 | 1.00 | MAPK1 (1.00) | MAPK1MAOAMAOBCISD1MITF | |
| Hiazolidinedione1 SCHEMBL15021963 | 0.99 | MAPK1 (0.98) | MAPK1MAOAMAOBCISD1MITF | |
| Hiazolidinedione1 SCHEMBL15021964 | 0.99 | MAPK1 (0.98) | MAPK1MAOAMAOBCISD1MITF | |
| SCHEMBL15817077 | 0.93 | MAPK1 (0.86) | MAPK1MAOAMAOBCISD1MITF | |
| SCHEMBL15817074 | 0.93 | MAPK1 (0.86) | MAPK1MAOAMAOBCISD1MITF | |
| SCHEMBL15817076 | 0.93 | MAPK1 (0.86) | MAPK1MAOAMAOBCISD1MITF | |
| SCHEMBL15818347 | 0.91 | MAPK1 (0.83) | MAPK1MAOAMAOBCISD1MITF | |
| SCHEMBL15818349 | 0.91 | MAPK1 (0.83) | MAPK1MAOAMAOBCISD1MITF | |
| SCHEMBL15818348 | 0.91 | MAPK1 (0.83) | MAPK1MAOAMAOBCISD1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200260-A1 | METHODS FOR DETERMINING AND INHIBITING RHEUMATOID ARTHRITIS ASSOCIATED WITH THE BRAF ONCOGENE IN A SUBJECT | THE UNITED STATES OF AMERICA AS REPRESENTED BY | 2014-07-17 | — | — | US | claimed |
| WO-2013001372-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ACTIVATION OF REGULATORY T CELLS | UNIVERSITY OF OSLO (NO) | 2013-01-03 | — | — | WO | claimed |
| EP-4606792-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | University of Maryland, Baltimore (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-3890733-B1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIV MARYLAND (US) | 2025-04-16 | — | — | EP | disclosed |
| US-12202810-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240366619-A1 | NON-CATALYTIC SUBSTRATE-SELECTIVE p38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-11-07 | — | — | US | disclosed |
| US-11911392-B2 | Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911393-B2 | Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3474835-B1 | NON-CATALYTIC SUBSTRATE-SELECTIVE P38 -SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | UNIV MARYLAND (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-2470898-A1 | DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT BY DETECTING KRAS MUTATION AND RTK EXPRESSION LEVELS | Genentech, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012019113-A2 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110110891-A1 | Methods of Treating Hepatitis C Virus Infection | NIH-DEITR | 2011-05-12 | — | — | US | disclosed |
| WO-2011028540-A1 | DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT BY DETECTING KRAS MUTATION AND RTK EXPRESSION LEVELS | GENENTECH, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20090239936-A1 | Prophylactic and Therapeutic Agent for Cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-2025347-A1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20080193504-A1 | Method to Treat and Prevent Posterior Capsule Opacification | THOMAS JEFFERSON UNIVERSITY | 2008-08-14 | — | — | US | disclosed |
| EP-1893292-A2 | METHOD TO TREAT AND PREVENT POSTERIOR CAPSULE OPACIFICATION | THOMAS JEFFERSON UNIVERSITY (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128152-A2 | METHOD TO TREAT AND PREVENT POSTERIOR CAPSULE OPACIFICATION | THOMAS JEFFERSON UNIVERSITY (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110891-A1 | Methods of Treating Hepatitis C Virus Infection | HAVCR2, HCCS, HDGF | MAPK1 405/4885MAOA 1857/4885MAOB 1012/4885 |
| US-20240366619-A1 | NON-CATALYTIC SUBSTRATE-SELECTIVE p38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF | MAPK1, MAPK7, MAPK8 | MAPK1 1/4885MAOA 3858/4885MAOB 4111/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | MAPK1 1/4885MAOA 4430/4885MAOB 4543/4885 |
| US-12202810-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | MAPK1, MAPK8, MAPK4 | MAPK1 1/4885MAOA 4430/4885MAOB 4543/4885 |
| US-11911392-B2 | Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | MAPK1, MAPK15, MAPK8 | MAPK1 1/4885MAOA 3939/4885MAOB 4123/4885 |
| US-11911393-B2 | Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | MAPK1, MAPK7, MAPK8 | MAPK1 1/4885MAOA 3858/4885MAOB 4111/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | MAPK1 1/4885MAOA 4430/4885MAOB 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.